Search results for " pharmacy"

showing 10 items of 365 documents

Sources of human plasma cyclic AMP. Examinations before and after beta 2 adrenergic stimulation.

1981

Plasma cyclic AMP was measured in different vessels in seventeen volunteers before and after stimulation with terbutaline. Differences between arterial blood and blood from the hepatic vein, right ventricle, inferior vena cava and a cubital vein could not be demonstrated. Only in the renal vein was the concentration of cyclic AMP decreased. Our results indicate that cyclic AMP is not generated from any specific isolated organ and that changes in cyclic AMP after subcutaneous injection of terbutaline reflect a general influence of this drug.

AdultMalemedicine.medical_specialtyInjections SubcutaneousTerbutalineStimulation030204 cardiovascular system & hematology030226 pharmacology & pharmacyBiochemistryInferior vena cava03 medical and health sciences0302 clinical medicineAdrenergic stimulationInternal medicineCyclic AMPTerbutalineMedicineHumansVeinAgedbusiness.industryBiochemistry (medical)Cell BiologyGeneral MedicineAdrenergic beta-AgonistsMiddle AgedStimulation Chemicalmedicine.anatomical_structureEndocrinologymedicine.veinVentriclecardiovascular systemArterial bloodRenal veinbusinessmedicine.drugThe Journal of international medical research
researchProduct

Cataracts and statins. A disproportionality analysis using data from VigiBase.

2019

The basis of the association between statin use and cataract has been explored using the World Health Organization (WHO) global database of individual case safety reports (ICSRs) for drug monitoring (VigiBase) through January 2019. The reporting odds ratios (RORs) as a measure of disproportionality for reported cataracts and individual statins have been calculated. Subgroup analyses according statin lipophilicity, sex, and age groups have been performed. Moreover, RORs have been calculated for non-statin lipid lowering drugs. An increased disproportionality have been found for most individual statins lovastatin: [ROR: 14.80, 95% confidence interval (CI): 13.30, 16.46)], atorvastatin (ROR: 3…

AdultMalemedicine.medical_specialtyStatinAdolescentmedicine.drug_classAtorvastatin010501 environmental sciencesToxicology030226 pharmacology & pharmacy01 natural sciencesRisk AssessmentCataract03 medical and health sciencesPharmacovigilanceYoung Adult0302 clinical medicineEzetimibeInternal medicinemedicineOdds RatioAdverse Drug Reaction Reporting SystemsHumansRosuvastatinChild0105 earth and related environmental sciencesAgedAged 80 and overbusiness.industryIncidenceGeneral MedicineOdds ratioMiddle AgedSimvastatinFemaleDrug MonitoringHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPravastatinmedicine.drugFluvastatinRegulatory toxicology and pharmacology : RTP
researchProduct

Pharmaceutical validation as a process of improving the quality of antineoplastic treatment

2006

Objective. To quantify the improvement added by standardization of pharmaceutical validation (PV) of antineoplastic treatment to the processes of prescription and preparation of the pharmacotherapeutic sequence, in terms of prevention and reduction of medication errors (ME). Design. Prospective cohort study during two years (from 2001-2002) for oncohaematologic patients (inpatients and outpatients) that compared the percentage of medication errors detected and resolved and the number of medication errors with potential clinical significance (severity value ≥4) intercepted during PV in both years. Results. During the PV processes, 202 ME were identified and resolved, which is the equivalent…

AdultMalemedicine.medical_specialtyTime FactorsAntineoplastic AgentsMedical Oncology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineHumansMedication ErrorsMedicinePharmacology (medical)Clinical significanceProspective StudiesMedical prescriptionProspective cohort studyAgedAged 80 and overInpatientsbusiness.industryHematologyMiddle AgedPrognosisSurgeryOncologyPharmaceutical Services030220 oncology & carcinogenesisFemalePatient CarebusinessHospital UnitsTotal Quality ManagementJournal of Oncology Pharmacy Practice
researchProduct

Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case report

2019

Abstract Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide advantages in treatment compliance, but data on their use in pregnancy are very limited. We present a clinical case of aripiprazole LAI use in pregnancy. Case presentation A 43-year-old woman diagnosed with bipolar disorder, with several relapses due to treatment interruption while trying to conceive. Finally, aripiprazole LAI treatment was planned by mutual agreement between doctor and the patient, who took aripiprazole LAI before and during pregnancy. She gave birth at 40 weeks to a 3500 g baby girl with no congenital malformations, who was healthy at 5 months after delivery. Conclusion As far …

AdultPediatricsmedicine.medical_specialtyTime FactorsBipolar disordermedicine.medical_treatmentvirusesAripiprazoleCase Report030226 pharmacology & pharmacyInjections IntramuscularAntipsychotic03 medical and health sciences0302 clinical medicineimmune system diseasesPregnancylcsh:RA1190-1270medicineHumansPharmacology (medical)Bipolar disorderAntipsychoticlcsh:Toxicology. PoisonsPharmacologyDosage FormsPregnancybusiness.industrylcsh:RM1-950Pregnancy Outcomevirus diseasesCongenital malformationsmedicine.diseasePregnancy ComplicationsLong actinglcsh:Therapeutics. PharmacologyTreatment interruptionLong-acting injectable aripiprazoleAripiprazoleFemaleClinical casebusinessmedicine.drugAntipsychotic AgentsFollow-Up StudiesBMC Pharmacology and Toxicology
researchProduct

Targeted Hybrid Nanocarriers as a System Enhancing the Skin Structure

2021

The skin is constantly exposed to external and internal factors that disturb its function. In this work, two nanosystems-levan nanoparticles and a surfactin-stabilized nanoemulsion were preserved (tested for microbial growth) and characterized (size, polydispersity, Zeta potential, and stability). The nanosystems were introduced in the model formulations-cream, tonic, and gel, and confirmed by TEM. The analysis showed that nanoemulsion has a spherical morphology and size 220–300 nm, while levan nanoparticles had irregular shapes independently of the use of matrix and with particle size (130–260 nm). Additionally, we examined the antiradical effect of levan nanoparticles and nanoemulsion in …

AdultskinMaterials scienceDPPHDispersitySkin CreamnanoemulsionPharmaceutical ScienceNanoparticleformulationMicrobial Sensitivity Tests02 engineering and technology030226 pharmacology & pharmacySkin DiscolorationsurfactinArticleAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:Organic chemistryIn vivoDrug DiscoveryZeta potentialHumansPhysical and Theoretical ChemistryDrug CarriersBacteriaanti-agingOrganic ChemistryMiddle Aged021001 nanoscience & nanotechnologyDynamic Light ScatteringlevanFructansSkin AgingchemistryChemistry (miscellaneous)Molecular MedicineEmulsionsFemalenanoparticlesParticle sizeNanocarriers0210 nano-technologyBiomedical engineeringMolecules
researchProduct

Neurofisiología y envejecimiento. Concepto y bases fisiopatológicas del deterioro cognitivo

2016

Brain ageing is produced by various morphological, biochemical, metabolic and circulatory changes, which are reflected in functional changes, whose impact depends on the presence or absence of cognitive impairment. Because of brain plasticity, together with redundancy of the distinct cerebral circuits, age- related deterioration of the brain at various levels does not always translate into loss of brain function. However, when the damage exceeds certain thresholds, there is age-related cognitive impairment, which increases the risk of developing various neurodegenerative diseases such as Alzheimer disease. Genetics, together with lifestyle, diet, and environmental factors, etc, can trigger …

AgingMedicine (miscellaneous)medicine.disease030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAgeing030220 oncology & carcinogenesisNeuroplasticitymedicineGeriatrics and GerontologyAlzheimer's diseasePsychologyCognitive impairmentNeuroscienceBrain functionRevista Española de Geriatría y Gerontología
researchProduct

GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease non-transgenic rat model

2015

Background: GABAergic inhibitory action regulates learning/memory processes and contributes to neurotransmission (Gong et al., 2009). Existing evidence suggests GABAergic system is involved in pathophysiology of Alzheimer’s disease (AD) via inhibitory interneuron deficits (Verret et al., 2012) and decrease in functional GABAA receptors (Limon et al., 2012). In vitro, GABA and muscimol (GABAA receptor agonist) blocked neuronal death induced by Aβ in rat hippocampal and cortical neurons (Paula-Lima et al., 2005). Our concept: low doses of muscimol may prevent learning/memory deficits in intracerebroventricular (icv) streptozocin (STZ)-induced AD non-transgenic rat model. Methods. Wistar male …

Agonistmedicine.medical_specialtymedicine.drug_class02 engineering and technologyWater mazeNeurotransmissionHippocampal formationInhibitory postsynaptic potential030226 pharmacology & pharmacymemory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineMultidisciplinarybusiness.industryGABAA receptorstreptozocin021001 nanoscience & nanotechnologymuscimol3. Good healthEndocrinologynervous systemMuscimolchemistryAnesthesiaPoster PresentationGABAergic0210 nano-technologybusinessSpringerPlus
researchProduct

Micellar liquid chromatography determination of rivaroxaban in plasma and urine. Validation and theoretical aspects.

2019

A Micellar Chromatographic method to determine rivaroxaban in plasma and urine has been developed. The samples were dissolved in the mobile phase (SDS 0.05 M – 1-propanol 12.5%, phosphate buffered at pH 7) and 20 μL directly injected, avoiding the extraction and purification steps. Using a C18 column and running under isocratic mode at 1 mL/min, analyte was eluted without interference from the matrix in <6.0 min. The detection absorbance wavelength was set to 250 nm. The procedure was validated by Food and Drug Administration guidelines in terms of: system suitability, calibration range (0.05–5 mg/L), linearity, sensitivity, robustness, carry-over effect, specificity, accuracy (−11.1 to 4.2…

AnalyteClinical Biochemistrypartition equilibriumUrine030226 pharmacology & pharmacy01 natural sciencesBiochemistryAnalytical Chemistrymicellar chromatographyMatrix (chemical analysis)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRivaroxabanLimit of Detectiondirect injectionHumansMicellesvalidationChromatographyElutionanticoagulant010401 analytical chemistryExtraction (chemistry)biological fluidReproducibility of ResultsCell BiologyGeneral MedicinePhosphate0104 chemical scienceschemistryMicellar liquid chromatographyPartition equilibriumLinear ModelsChromatography LiquidJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways …

2018

A semi-physiological two compartment pharmacokinetic model with two active metabolites (primary (PM) and secondary metabolites (SM)) with saturable and non-saturable pre-systemic efflux transporter, intestinal and hepatic metabolism has been developed. The aim of this work is to explore in several scenarios which analyte (parent drug or any of the metabolites) is the most sensitive to changes in drug product performance (i.e. differences in in vivo dissolution) and to make recommendations based on the simulations outcome. A total of 128 scenarios (2 Biopharmaceutics Classification System (BCS) drug types, 2 levels of KM Pgp, in 4 metabolic scenarios at 2 dose levels in 4 quality levels of t…

AnalyteCmaxPharmaceutical ScienceAdministration Oral02 engineering and technologyEquivalence Trials as TopicPharmacologyBioequivalence030226 pharmacology & pharmacyModels Biological03 medical and health sciencesFirst pass effect0302 clinical medicinePharmacokineticsHumansComputer SimulationPharmacokineticsIntestinal MucosaBiotransformationChemistryMembrane Transport Proteins021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemNONMEMNonlinear DynamicsPharmaceutical PreparationsSolubilityTherapeutic EquivalencyResearch DesignArea Under CurveLinear Models0210 nano-technologyMonte Carlo MethodDrug metabolismEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Relationship between particle size and dissolution rate of bulk powders and sieving characterized fractions of two qualities of orthoboric acid

1996

Drug Dev. Ind. Pharm. ISI Document Delivery No.: VN279 Times Cited: 1 Cited Reference Count: 22 Tromelin, A Habillon, S Andres, C Pourcelot, Y Chaillot, B; International audience; We have carried out a study of the particle size distribution and aqueous dissolution rate of two commercially available qualities of orthoboric acid, labeled ''crystal'' (ABC) and ''powder'' (ABP). In a previous work, we have shown that the two commercial qualities of orthoboric acid chosen as model compound (''powder'' and ''crystal'') are related to the same crystal network in spite of their different names. However, these two qualities have very different size particle distributions, as previously determined b…

Analytical chemistryPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacyrelease03 medical and health sciences0302 clinical medicine[CHIM.ANAL]Chemical Sciences/Analytical chemistryDrug DiscoverymorphologySize fractionsDissolution testingdissolution rateDissolutionfractal geometryPharmacologyAqueous solutionChemistryOrganic Chemistryparticle size021001 nanoscience & nanotechnologyLaser light scattering[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistryCrystallography[SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacologyParticle-size distributionParticle size0210 nano-technology
researchProduct